Triamcinolone Hexacetonide Injectable Suspension, chemical structure, molecular formula, Reference Standards
Triamcinolone Hexacetonide Injectable Suspension
»Triamcinolone Hexacetonide Injectable Suspension is a sterile suspension of Triamcinolone Hexacetonide in a suitable aqueous medium.It contains not less than 90.0percent and not more than 115.0percent of the labeled amount of C30H41FO7.
Packaging and storage
Preserve in single-dose or in multiple-dose containers,preferably of Type Iglass.
USP Reference standards á11ñ
USP Triamcinolone Hexacetonide RS.USP Endotoxin RS.
Place a volume of Injectable Suspension,equivalent to about 25mg of triamcinolone hexacetonide,and 2mLof water in a membrane filter having a pore size of 0.20µm.Apply vacuum to the filter,wash the residue with two 5-mLportions of water,and air-dry the filter and the precipitate.Place the dried filter and precipitate in a small beaker with 5mLof alcohol,and dissolve the precipitate.Decant the alcohol solution into a small beaker,and evaporate,with the aid of low heat and a current of air,to dryness:the triamcinolone hexacetonide so obtained responds to the Identificationtest under Triamcinolone Hexacetonide.
Bacterial endotoxins á85ñ
It contains not more than 17.2USP Endotoxin Units per mg of triamcinolone hexacetonide.
between 4.0and 8.0.
Limit of triamcinolone acetonide
,System suitability solution,and Chromatographic systemProceed as directed in the Assay.
and Test solutionUse the Standard preparationand the Assay preparation,respectively,and proceed as directed in the Assay.
Separately inject equal volumes (about 10µL)of the Standard solutionand the Test solutioninto the chromatograph,record the chromatograms,and measure the responses for all of the peaks.The Test solutionmay exhibit a minor peak for triamcinolone acetonide whose retention time is 0.22relative to triamcinolone hexacetonide.Calculate the percentage of triamcinolone acetonide in the portion of Injectable Suspension taken by the formula:
in which Cis the concentration,in mg per mL,of USP Triamcinolone Hexacetonide RSin the Standard solution,Dis the concentration,in mg per mL,of triamcinolone hexacetonide in the Test solution,and rUand rSare the peak responses for triamcinolone acetonide obtained for the Test solutionand Standard solution,respectively:not more than 1.0%is found.
It meets the requirements under Injections á1ñ.
and Standard preparationProceed as directed in the Assayunder Triamcinolone Hexacetonide.
System suitability solution
Dissolve suitable quantities of amcinonide and USP Triamcinolone Hexacetonide RSin methanol to obtain a solution containing about 0.3mg per mLand 0.4mg per mL,respectively.
Using a to containpipet,transfer an accurately measured volume of the Injectable Suspension,equivalent to about 40mg of triamcinolone hexacetonide,to a 100-mLvolumetric flask.Rinse the pipet with methanol,collecting the rinse in the volumetric flask.Dilute with methanol to volume,and mix.
(see Chromatography á621ñ)The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm ×25-cm column that contains packing L1.The flow rate is about 1.4mLper minute.Chromatograph the System suitability solution,and record the peak responses as directed for Procedure:the relative retention times are about 0.50for amcinonide and 1.0for triamcinolone hexacetonide,the resolution,R,between amcinonide and triamcinolone hexacetonide is not less than 10,the tailing factor for triamcinolone hexacetonide is not more than 1.2,and the relative standard deviation for replicate injections is not more than 2.0%.
Separately inject equal volumes (about 10µL)of the Standard preparationand the Assay preparationinto the chromatograph,record the chromatograms,and measure the responses for the major peaks.Calculate the quantity,in mg,of C30H41FO7in the portion of Injectable Suspension taken by the formula:
in which Cis the concentration,in mg per mL,of USP Triamcinolone Hexacetonide RSin the Standard preparation,and rUand rSare the peak responses obtained from the Assay preparationand the Standard preparation,respectively.
Staff Liaison:Clydewyn M.Anthony,Ph.D.,Scientist
Expert Committee:(PA1)Pharmaceutical Analysis 1
信息录入：awin 责任编辑：awin 【发表评论